ASMB

Several events have impacted ASMB stock over the past six months. In October 2026, the company announced it would present positive Phase 1a data for ABI-6250. In September 2026, Assembly Biosciences exercised its U.S. profit-share option with Gilead for the HSV helicase-primase inhibitor program, which was seen as raising revenue potential. In August 2026, the company reported Second Quarter 2026 financial results, showing a narrower loss and increased revenue, leading to a roughly 10% stock jump. In May 2026, the company announced the expansion of its ABI-6250 clinical development. The stock experienced a 1-month change of -28.4% and a 6-month change of -24.54% between September and October 2026, fluctuating between a low of $21.80 and a high of $39.71 over the last year.